Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

NCT06883552 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT06883552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06883552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
Lead sponsor
Sichuan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
October 1, 2026
Enrollment
21 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)